Dermavant Sciences: Dermavant to Present New Data from the P

- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical

Related Keywords

United States , Boston , Massachusetts , America , American , Laurence Watts , Melinda Gooderham , Annam Tallman , Angela Salerno Robin , Philipm Brown , Laurak Ferris , Kostenloser Wertpapierhandel , Aprilw Armstrong , Benjamin Ehst , Davids Rubenstein , Seemalr Desai , Program For Tapinarof , Exhibition Center , Twitter , Drug Administration , American Academy Of Dermatology , Boston Convention , Roivant Sciences , Dermavant Sciences , Linkedin Dermavant Sciences , Annual Meeting , New Drug Application , Prescription Drug User Fee Act , Tapinarof Cream , Once Daily , Plaque Psoriasis , Secondary Efficacy Outcomes , Long Term Extension , Psoriasis Area , Severity Index , Linda Stein Gold , Jerry Bagel , Dermatology Life Quality Index , Local Tolerability Scores , Leon Kircik , North America , Vice President , Media Relations , Dermavant , Ciences , Present , Data , Rom , Hase , Soaring , Song , Term , Extension , Trial , Tapinarof , Cream , Adults , Plaque , Psoriasis , 022 , Academy , Ermatology , Nnual , Meeting ,